Evercore ISI Reiterates Bullish View on Adamas Pharmaceuticals (ADMS)

Evercore ISI analyst Josh Schimmer reiterated an Outperform rating and $45.00 price target on Adamas Pharmaceuticals (NASDAQ: ADMS) following negative data.

Schimmer said they are optimistic this marks the final of many mistakes from prior management and now the new team can execute on Gocovri for LID with a clean slate and lightly explore other pipeline opportunities.

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $7.30 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy
• HSBC Upgrades YPF S.A. (YPF) to Buy